drugset / Trial / NCT00958334

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

NCT00958334

Phase 2 Completed 65 enrolled Repros Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258) to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study.

Timeline

Start
2006-09-07
Primary completion
2008-10-15
Completion
2008-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 12.5 mg
Subject Telapristone Acetate Other / unclassified 25 mg

Indications